Navigation Links
Sanofi-aventis to Acquire TargeGen, Inc.
Date:6/30/2010

SAN DIEGO, June 30 /PRNewswire/ -- TargeGen, Inc., a privately held biotechnology company focused on the development of small molecule kinase inhibitors today announced that the Company has agreed to be acquired by sanofi-aventis (EURONEXT: SAN; NYSE: SNY). Under the agreement, the ultimate purchase price will depend on the achievement of certain future milestones events and will total $560M if such milestones are fully realized. The closing of the transaction is expected to occur in the 3rd quarter of 2010.

(Logo: http://photos.prnewswire.com/prnh/20030430/TARGEGENLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20030430/TARGEGENLOGO)

Formed in 2001, TargeGen's most advanced drug candidate is TG101348, an internally discovered, oral, potent, and highly selective JAK2 kinase inhibitor being developed for the treatment of patients with myeloproliferative diseases including primary and secondary myelofibrosis (MF) and polycythemia vera (PV). There are currently no approved drugs to treat MF or PV. Preliminary data from a 59 patient trial involving the treatment of MF patients with TG101348 were presented at the American Society of Hematology (ASH) Conference in New Orleans in December 2009. Other pre-clinical data presented at the 2009 ASH meetings by academic collaborators of the Company suggest that in addition to the treatment of certain myeloproliferative disorders, TG101348 may also have potential utility in the treatment of certain forms of leukemia, lymphoma, other hematological malignancies and blood disorders.

"Sanofi-aventis brings significant strength and resources to the continued development and potential commercialization of TG101348. With their global focus on oncology and long term commitment to this patient population, we are confidant they will maximize the treatment potential of TG101348 across multiple clinical indications," said Peter G. Ulrich, President, CEO and Co-Founder of TargeGen. "Further, their decision to acquire TargeGen at this time validates the Company's belief that TG101348 has the potential to be the best in class compound in terms of providing meaningful new treatment options for patients with myeloproliferative diseases and certain other hematological malignancies."

Peter J. Solomon Company served as financial advisors to TargeGen relative to this transaction.

www.targegen.com


'/>"/>
SOURCE TargeGen, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ascenta Therapeutics Licenses Cancer Drug Candidates to sanofi-aventis
2. Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF
3. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
4. The Foundation for National Institutes of Health Announces Unprecedented Product Donation by sanofi-aventis in the U.S.
5. Sanofi-aventis U.S. Introduces BenzaClin(R) Carekit
6. Sanofi-aventis Announces Second Quarter 2009 Results
7. Sanofi-aventis U.S. Announces Settlement of Medicaid Best Price Investigation
8. Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
9. BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis
10. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
11. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016   EpiBiome , a precision microbiome engineering ... debt financing from Silicon Valley Bank (SVB). The financing ... advance its drug development efforts, as well as purchase ... "SVB has been an incredible strategic partner to us ... bank would provide," said Dr. Aeron Tynes Hammack ...
(Date:6/23/2016)... ON (PRWEB) , ... June 23, 2016 , ... STACS ... DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as ... the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
Breaking Biology Technology:
(Date:6/7/2016)... June 7, 2016  Syngrafii Inc. and San ... relationship that includes integrating Syngrafii,s patented LongPen™ eSignature ... This collaboration will result in greater convenience for ... union, while maintaining existing document workflow and compliance ... ...
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
Breaking Biology News(10 mins):